CCL

Összesen 3 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM104496
035-os BibID:(scopus)85132856048 (wos)000816988100001
Első szerző:Blennow, Ola
Cím:Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies : an EPICOVIDEHA survey report / Blennow Ola, Salmanton-García Jon, Nowak Piotr, Itri Federico, Van Doesum Jaap, López-García Alberto, Farina Francesca, Jaksic Ozren, Pinczés László Imre, Bilgin Yavuz M., Falces-Romero Iker, Jiménez Moraima, Ormazabal-Vélez Irati, Weinbergerová Barbora, Duléry Rémy, Stojanoski Zlate, Lahmer Tobias, Fernández Noemí, Hernández-Rivas José-Ángel, Petzer Verena, De Jonge Nick, Glenthj Andreas, De Ramón Cristina, Biernat Monika M., Fracchiolla Nicola, Aujayeb Avinash, Van Praet Jens, Schönlein Martin, Méndez Gustavo-Adolfo, Cattaneo Chiara, Guidetti Anna, Sciume Mariarita, Ammatuna Emanuele, Cordoba Raul, García-Poutón Nicole, Gräfe Stefanie, Cabirta Alba, Wolf Dominik, Nordlander Anna, García-Sanz Ramón, Delia Mario, Berg Venemyr Caroline, Brones Clara, Di Blasi Roberta, De Kort Elizabeth, Meers Stef, Lamure Sylvain, Serrano Laura, Merelli Maria, Coppola Nicola, Bergantim Rui, Besson Caroline, Kohn Milena, Petiti Jessica, Garcia-Vidal Carolina, Dargenio Michelina, Danion Francois, Machado Marina, Bailén-Almorox Rebeca, Hoenigl Martin, Dragonetti Giulia, Chai Louis Yi Ann, Kho Chi Shan, Bonanni Matteo, Liévin Raphaël, Marchesi Francesco, Cornely Oliver A., Pagano Livio
Dátum:2022
ISSN:0361-8609 1096-8652
Tárgyszavak:Orvostudományok Klinikai orvostudományok levél
folyóiratcikk
Megjelenés:American Journal of Hematology. - 97 : 8 (2022), p. E312-E317. -
További szerzők:Salmanton-García, Jon Nowak, Piotr Itri, Federico van Doesum, Jaap López-García, Alberto Farina, Francesca Jaksic, Ozren Pinczés László Imre (1990-) (általános orvos) Bilgin, Yavuz M. Falces-Romero, Iker Jiménez, Moraima Ormazabal-Vélez, Irati Weinbergerová, Barbora Duléry, Rémy Stojanoski, Zlate Lahmer, Tobias Fernández, Noemí Hernández-Rivas, José-Ángel Petzer, Verena de Jonge, Nick Glenthj, Andreas De Ramón, Cristina Biernat, Monika M. Fracchiolla, Nicola S. Aujayeb, Avinash van Praet, Jens Schönlein, Martin Méndez, Gustavo-Adolfo Cattaneo, Chiara Guidetti, Anna Sciumè, Mariarita Ammatuna, Emanuele Cordoba, Raul García-Poutón, Nicole Gräfe, Stefanie Cabirta, Alba Wolf, Dominik Nordlander, Anna García-Sanz, Ramón Delia, Mario Berg Venemyr, Caroline Brones, Clara Di Blasi, Roberta De Kort, Elizabeth Meers, Stef Lamure, Sylvain Serrano, Laura Merelli, Maria Coppola, Nicola Bergantim, Rui Besson, Caroline Kohn, Milena Petiti, Jessica Garcia-Vidal, Carolina Dargenio, Michelina Danion, Francois Machado, Marina Bailén-Almorox, Rebeca Hoenigl, Martin Dragonetti, Giulia Chai, Louis Yi Ann Kho, Chi Shan Bonanni, Matteo Liévin, Raphaël Marchesi, Francesco Cornely, Oliver Andreas Pagano, Livio
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM106190
035-os BibID:(WoS)000922296500001 (Scopus)85142183130
Első szerző:Pagano, Livio
Cím:Breakthrough COVID-19 in vaccinated patients with hematologic malignancies : results from the EPICOVIDEHA survey / Pagano Livio, Salmanton-García Jon, Marchesi Francesco, Blennow Ola, Gomes da Silva Maria, Glenthj Andreas, van Doesum Jaap, Bilgin Yavuz M., López-García Alberto, Itri Federico, Nunes Rodrigues Raquel, Weinbergerová Barbora, Farina Francesca, Dragonetti Giulia, Berg Venemyr Caroline, van Praet Jens, Jaksic Ozren, Valkovic Toni, Falces-Romero Iker, Martín-Pérez Sonia, Jiménez Moraima, Dávila-Valls Julio, Schönlein Martin, Ammatuna Emanuele, Meers Stef, Delia Mario, Stojanoski Zlate, Nordlander Anna, Lahmer Tobias, Imre Pinczés László, Buquicchio Caterina, Piukovics Klára, Ormazabal-Vélez Irati, Fracchiolla Nicola, Samarkos Michail, Méndez Gustavo-Adolfo, Hernández-Rivas José-Ángel, Espigado Ildefonso, Cernan Martin, Petzer Verena, Lamure Sylvain, di Blasi Roberta, Marques de Almedia Joyce, Dargenio Michelina, Biernat Monika M., Sciume Mariarita, de Ramón Cristina, de Jonge Nick, Batinic Josip, Aujayeb Avinash, Marchetti Monia, Fouquet Guillemette, Fernández Noemí, Zambrotta Giovanni, Sacchi Maria Vittoria, Guidetti Anna, Demirkan Fatih, Prezioso Lucia, Rácil Zdenek, Nucci Marcio, Mladenovic Milos, Liévin Raphaël, Hanáková Michaela, Gräfe Stefanie, Sili Uluhan, Machado Marina, Cattaneo Chiara, Adzic-Vukicevic Tatjana, Verga Luisa, Labrador Jorge, Rahimli Laman, Bonanni Matteo, Passamonti Francesco, Pagliuca Antonio, Corradini Paolo, Hoenigl Martin, Koehler Philipp, Busca Alessandro, Cornely Oliver A., EPICOVIDEHA Survey
Dátum:2022
ISSN:0006-4971
Megjegyzések:Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccination. Adult patients with HM, >= 1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received <= 2 vaccine doses before COVID-19 (1419, 91%), mostly mRNAbased (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P <.001), active HM (P <.001), and severe and critical COVID-19 (P =.007 and P <.001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P <.001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P <.001) or combined with antivirals (P =.009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Blood. - 140 : 26 (2022), p. 2773-2787. -
További szerzők:Salmanton-García, Jon Marchesi, Francesco Blennow, Ola Gomes Da Silva, Maria Glenthj, Andreas van Doesum, Jaap Bilgin, Yavuz M. López-García, Alberto Itri, Federico Nunes Rodrigues, Raquel Weinbergerová, Barbora Farina, Francesca Dragonetti, Giulia Berg Venemyr, Caroline van Praet, Jens Jaksic, Ozren Valkovic, Toni Falces-Romero, Iker Martín-Pérez, Sonia Jiménez, Moraima Dávila-Valls, Julio Schönlein, Martin Ammatuna, Emanuele Meers, Stef Delia, Mario Stojanoski, Zlate Nordlander, Anna Lahmer, Tobias Pinczés László Imre (1990-) (általános orvos) Buquicchio, Caterina Piukovics Klára Ormazabal-Vélez, Irati Fracchiolla, Nicola S. Samarkos, Michail Méndez, Gustavo-Adolfo Hernández-Rivas, José-Ángel Espigado, Ildefonso Cernan, Martin Petzer, Verena Lamure, Sylvain Di Blasi, Roberta Marques de Almedia, Joyce Dargenio, Michelina Biernat, Monika M. Sciumè, Mariarita De Ramón, Cristina de Jonge, Nick Batinić, Josip Aujayeb, Avinash Marchetti, Monia Fouquet, Guillemette Fernández, Noemí Zambrotta, Giovanni Paolo Maria Sacchi, Maria Vittoria Guidetti, Anna Demirkan, Fatih Prezioso, Lucia Ráčil, Zdenĕk Nucci, Marcio Mladenović, Miloš Liévin, Raphaël Hanáková, Michaela Gräfe, Stefanie Sili, Uluhan Machado, Marina Cattaneo, Chiara Adžić-Vukičević, Tatjana Verga, Luisa Labrador, Jorge Rahimli, Laman Bonanni, Matteo Passamonti, Francesco Pagliuca, Antonio Corradini, Paolo Hoenigl, Martin Koehler, Philipp Busca, Alessandro Cornely, Oliver Andreas EPICOVIDEHA Survey
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM113120
035-os BibID:(cikkazonosító)101939 (scopus)85151507775
Első szerző:Salmanton-García, Jon
Cím:Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies : a report from the EPICOVIDEHA registry / Salmanton-García Jon, Marchesi Francesco, Gomes da Silva Maria, Farina Francesca, Dávila-Valls Julio, Bilgin Yavuz M., Glenthj Andreas, Falces-Romero Iker, Van Doesum Jaap, Labrador Jorge, Buquicchio Caterina, El-Ashwah Shaimaa, Petzer Verena, Van Praet Jens, Schönlein Martin, Dargenio Michelina, Méndez Gustavo-Adolfo, Meers Stef, Itri Federico, Giordano Antonio, Pinczés László Imre, Espigado Ildefonso, Stojanoski Zlate, López-García Alberto, Prezioso Lucia, Jaksic Ozren, Vena Antonio, Fracchiolla Nicola S., González-López Tomás José, Colovic Natasa, Delia Mario, Weinbergerová Barbora, Marchetti Monia, Marques de Almeida Joyce, Finizio Olimpia, Besson Caroline, Biernat Monika M., Valkovic Toni, Lahmer Tobias, Cuccaro Annarosa, Ormazabal-Vélez Irati, Batinic Josip, Fernández Noemí, De Jonge Nick, Tascini Carlo, Anastasopoulou Amalia N., Duléry Rémy, Del Principe Maria Ilaria, Plantefeve Gaëtan, Papa Mario Virgilio, Nucci, Marcio; Jiménez, Moraima; Aujayeb, Avinash; Hernández-Rivas, José-Ángel; Merelli, Maria; Cattaneo, Chiara; Blennow, Ola; Nordlander, Anna; Cabirta, Alba; Varricchio, Gina; Sacchi, Maria Vittoria; Cordoba, Raul; Arellano, Elena; Gräfe, Stefanie K.; Wolf, Dominik, Emarah Ziad, Ammatuna Emanuele, Hersby Ditte Stampe, Martín-Pérez Sonia, Nunes Rodrigues, Raquel Rahimli, Laman, Pagano Livio, Cornely Oliver A., EPICOVIDEHA registry
Dátum:2023
ISSN:2589-5370
Megjegyzések:Background Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. eClinicalMedicine 2023;58: 101939 Published Online 6 April 2023 https://doi.org/10. 1016/j.eclinm.2023. 101939 Articles 2 www.thelancet.com Vol 58 April, 2023 Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan?Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ?1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448?4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619?8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093?0.732) and obesity (aOR 0.105, 95%CI 0.014?0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was observed explaining the mortality difference in patients after nirmatrelvir/ritonavir administration. Interpretation Haematological malignancy patients were more likely to receive nirmatrelvir/ritonavir when reporting extrapulmonary symptoms or 2nd vaccine booster at COVID-19 onset, as opposed to chronic pulmonary disease and obesity. The mortality rate in patients treated with nirmatrelvir/ritonavir was lower than in patients with targeted drugs other than nirmatrelvir/ritonavir.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Nirmatrelvir
SARS-CoV-2
Haematology
Malignancy
COVID-19
Megjelenés:eClinicalMedicine. - 58 (2023), p. 1-19. -
További szerzők:Marchesi, Francesco Gomes Da Silva, Maria Farina, Francesca Dávila-Valls, Julio Bilgin, Yavuz M. Glenthj, Andreas Falces-Romero, Iker van Doesum, Jaap Labrador, Jorge Buquicchio, Caterina El-Ashwah, Shaimaa Petzer, Verena van Praet, Jens Schönlein, Martin Dargenio, Michelina Méndez, Gustavo-Adolfo Meers, Stef Itri, Federico Giordano, Antonio Pinczés László Imre (1990-) (általános orvos) Espigado, Ildefonso Stojanoski, Zlate López-García, Alberto Prezioso, Lucia Jaksic, Ozren Vena, Antonio Fracchiolla, Nicola S. González-López, Tomás José Colovic, Natasa Delia, Mario Weinbergerová, Barbora Marchetti, Monia Marques de Almedia, Joyce Finizio, Olimpia Besson, Caroline Biernat, Monika M. Valkovic, Toni Lahmer, Tobias Cuccaro, Annarosa Ormazabal-Vélez, Irati Batinić, Josip Fernández, Noemí de Jonge, Nick Tascini, Carlo Anastasopoulou, Amalia N. Duléry, Rémy Del Principe, Maria Ilaria Plantefeve, Gaëtan Papa, Mario Virgilio Nucci, Marcio Jiménez, Moraima Aujayeb, Avinash Hernández-Rivas, José-Ángel Merelli, Maria Cattaneo, Chiara Blennow, Ola Nordlander, Anna Cabirta, Alba Varricchio, Gina Sacchi, Maria Vittoria Cordoba, Raul Arellano, Elena Gräfe, Stefanie K. Wolf, Dominik Emarah, Ziad Ammatuna, Emanuele Hersby, Ditte Stampe Martín-Pérez, Sonia Nunes Rodrigues, Raquel Rahimli, Laman Pagano, Livio Cornely, Oliver Andreas EPICOVIDEHA registry
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1